Ten years after ruxolitinib approval for myelofibrosis: A review of clinical efficacy
N Pemmaraju, P Bose, R Rampal, AT Gerds… - Leukemia & …, 2023 - Taylor & Francis
Myelofibrosis (MF) is a chronic myeloproliferative neoplasm characterized by splenomegaly,
abnormal cytokine expression, cytopenias, and progressive bone marrow fibrosis. The …
abnormal cytokine expression, cytopenias, and progressive bone marrow fibrosis. The …
BCR:: ABL1 negative myeloproliferative neoplasms: A review focused on essential thrombocythemia and polycythemia vera
M Khodier, K Gadó - Physiology International, 2023 - akjournals.com
The classical myeloproliferative neoplasms are divided into chronic myeloid leukemia, and
the Philadelphia negative polycythemia vera, essential thrombocythemia and primary …
the Philadelphia negative polycythemia vera, essential thrombocythemia and primary …
The aetiology and burden of myeloproliferative neoplasms in the United Kingdom: the MyelOproliferative neoplasmS: an In-depth case-control (MOSAICC) study …
N Abutheraa, EL Tarburn, CM McShane, A Duncombe… - BMC cancer, 2023 - Springer
Abstract Background Myeloproliferative neoplasms (MPNs) are a group of haematological
malignancies that affect approximately 8 people in every 100,000 individuals in the UK. Little …
malignancies that affect approximately 8 people in every 100,000 individuals in the UK. Little …
Efficacy and safety of ruxolitinib vs best available therapy for polycythemia vera: An updated systematic review and meta‐analysis
MM Roca Mora, F Afzal, CR Guimaraes, LM Cunha… - APMIS, 2024 - Wiley Online Library
Ruxolitinib, a JAK1/JAK2 inhibitor, has been shown to have lower thromboembolism rates
compared to placebo in polycythemia vera (PV) patients. This meta‐analysis evaluates …
compared to placebo in polycythemia vera (PV) patients. This meta‐analysis evaluates …
Translation, Cultural Adaptation, and Validation into Romanian of the Myeloproliferative Neoplasm Symptom Assessment Form—Total Symptom Score (MPN-SAF …
Background: Patients with myeloproliferative neoplasms (MPNs) experience a high disease-
related symptom burden. A specific instrument to evaluate quality of life (QoL), ie, the MPN …
related symptom burden. A specific instrument to evaluate quality of life (QoL), ie, the MPN …
Expression of CD4+ T Cells in Myeloproliferative Diseases and the Effect of Ruxolitinib Treatment on Prognosis
X Song, S Dong, Y Yang, C Zhang, J Sun… - The Tohoku Journal of …, 2024 - jstage.jst.go.jp
Myeloproliferative disorders (MPDs) are rare diseases in which the bone marrow produces
too many red, white, or platelets. Myeloproliferative disorders are neither acute nor …
too many red, white, or platelets. Myeloproliferative disorders are neither acute nor …
[PDF][PDF] Myeloproliferative Neoplasm Symptom Assessment Total Symptom Score (MPN-SAF TSS) in Chronic Myeloproliferative Neoplasms, Related with Genetic …
E Ümit, M Baysal, HO Kırkızlar… - Turkish Journal of …, 2024 - jag.journalagent.com
Abstract Myeloproliferative Neoplasm Symptom Assessment Total Symptom Score (MPN-
SAF TSS) is a surrogate marker for symptom evaluation in Chronic Myeloproliferative …
SAF TSS) is a surrogate marker for symptom evaluation in Chronic Myeloproliferative …
[PDF][PDF] The Impact of Current Treatment on The Symptomatology and Complications of Patients with Polycythemia Vera
MT DAMIAN, L URIAN, A BOJAN - Revista Romana de Hematologie, 2024 - dhrrh.ro
Introduction: polycythemia vera is a Ph negative relatively indolent chronic
myeloproliferative disease, with a high risk of arterial and venous thrombosis, affecting …
myeloproliferative disease, with a high risk of arterial and venous thrombosis, affecting …